Brand managers and marketing leads are always striving to gain that first step of engagement, particularly in our world of pharmaceutical manufacturing. And with good reason. Customer engagement leads to improved understanding, which drives loyalty and ultimately improved health.
Eric Boothe, Director Business DevelopmentâLife Sciences
Since the very dawn of Western capitalism, competition has been synonymous with success. Indeed, in accounting for the past 500 years of Western ascendancy in the world, Professor Niall Ferguson of Harvard University points to six âkiller appsâ. The first of these, unsurprisingly, is competition
Earlier this month the UK drugs giant GlaxoSmithKline announced a groundbreaking and progressive new scheme for graduates, whereby from 2012 the company will offer to reimburse in full the university tuition fees of the entirety its future graduate intake.
After six months of sometimes lively pursuit, the French pharmaceutical group, Sanofi-aventis, has agreed a deal to pay $20.1bn in cash for U.S. biotech firm Genzyme Corp after Sanofi made an increased offer of $74 per share.
Max Golby - PharmiWeb Field Reporter
Social networking sites such as Facebook, Linkedin and Twitter are all the rage â thereâs no escaping them, theyâre everywhere â even in the workplace, and whether you like it or not, theyâre not going away.
Catherine Gutsell, CK Group
If you've got your self an interview for the perfect job - well done! Now comes the hard part, and you only get one chance.
So, here's a simple check list of things that should help you keep your cool and allow you to concentrate on sailing through the interview
If you are new to using PharmiWeb.com to find a new job, you'll soon realise that we have thousands of jobs listed and that they change every day. This means you may initially find the task a bit daunting.
However, itâs not really that hard, and with a bit of thought, you will soon be asking why you didnât do it years ago.
When David Cameron recently found himself in the hot seat on the BBCâs Andrew Marr Show, one policy area brought challenges beyond all others. Healthcare reform, Mr. Marr suggested in a short exchange, is swiftly becoming a major source of controversy for this government.
As a result of a vote taken in the European Parliament earlier this week, patients in the European Union will receive improved information on prescription drugs, in addition to being protected from some of the more potentially exploitable clauses of the Commissionâs proposed Directive on Information to Patients.
In an age of competition and choice, patient knowledge is paramount. Between 1997 and 2007, the Blair governmentâs entire programme of public sector reforms were delivered under the banner of âChoice and Competitionâ.
With the global economy remaining stagnant, big pharma companies are keen to develop blockbuster drugs that have a high financial ceiling. Rodger McMillan, VP of R&D at Astra Zeneca has said that âbig pharma is a cash-rich industry â it has to be,â namely because of the huge costs in developing new drugs â sometimes as much as $200 million.
In the USA alone, when your neighbor is out of work it is a slowdown, when your
family member is added it becomes recession and when you too join the same line
than it surely becomes a depression. The unofficial employment in USA being claimed at 15-25 percent while the economical turnaround seems a mirage; the closer you get the clearer becomes the reality, nothing but refractions.
In many ways, the National Institute for Health and Clinical Excellence (NICE) embodies many of the characteristics that define the NHS. In a system of universal access â and in a world where resources are finite â tough decisions inevitably have to be made. And by taking difficult decisions, particularly in reference to end of life care, NICE attempts to make the most of the drugs budget we do have.
Epratuzumab, a new humanised IgG1 monoclonal antibody that acts on CD22 (a molecule preventing over-activation of the immune system and emergence of auto-immune diseases) has shown promise as a potential treatment of moderate to severe systemic lupus erythematosus (SLE) according to results of a new study EMBLEM.
Olwen Glynn Owen
Large pharma has been seeking new biomarkers for years â all part of their drug discovery process, but often only as an afterthought in the development process. Thatâs changed over recent years, but by-and-large the bulk of biomarker work remains in the hands of small -to -medium-sized companies whose focused approach is more attuned to biomarkers being a major element of a final product.
Most pharmacologists will acknowledge that nutrition is important for good health and well-being, however, at the same time it is also considered to be a chemical nightmare with unknown effects. This has not always been the case, in the past connections between pharmacology and nutrition has been more intimate, as Hippocrates once stated, ââLet food be thy medicine and let medicine be thy food.
Johan Garssen, PhD, Conference Chairman
Reshaping the pharmaceutical industry's quality standards is currently the top priority for the Chinese government. Earlier announcements by its Ministry of Health to issue new tougher Good Manufacturing Processes (GMP) standards for medical products comes at the right time as current regulations do not meet international standards which result in poor performance by Chinese companies in the international market.
Now more than ever, alternative science and holistic remedies are playing a role in our lifestyles. But is that right? Over the past year, we've reported on everything from homeopathy to hypnotherapy. Importantly, we've differentiated between those approaches with at least a modicum of evidence to support them, and those without almost any at all. Yet in contrast to homeopathy, perhaps it can be said that our next target has at least a little science to support it.
Last week Pharmaceutical heads met as a result of a drugs recall after a pill mix up of breast cancer pills. The drug, Fresenius Kabiâs Anastrozole, was made by the German companyâs subsidiary in India. The ingredient mix up led to the voluntary recall of 7,192 bottles, each containing 30 tablets.
Emma Naylor- NG Online
As Republican Congressmen line up to attack Barack Obamaâs landmark U.S. healthcare reforms ahead of next monthâs mid-term elections, reforms on this side of the Atlantic are receiving equally forceful criticism.
Out there on the branding battlefields its simply do or die as brand images are either hyper visible or mortally lost in oblivion. Commanding success for any idea on the global scene demands universal access on e-commerce that is only deliverable by a cyber name identity, as it's the only key to open the site.
The Kingdom of Saudi Arabia provides a new opportunity for clinical research, and can open doors to untapped populations, explains Rani Abraham at ClinTec International
Rani Abraham - ClinTec International
With access, cost and quality concerns plaguing pharmaceutical delivery systems both in the US as well as globally, the Next Generation Pharmaceutical Drug Discovery committee has been formed to confront, assess and deliver new strategies to secure the future of the industry.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her